Sporotrichosis

Sporotrichosis is a systemic fungal infection caused by pathogenic fungi of the genus Sporothrix. Most often, the disease manifests itself in the form of skin lesions, but in severe cases it can affect the lymphatic, bone, pulmonary and even generalized forms. The main causative agent of sporotrichosis is Sporothrix schenckii, which lives in soil and vegetation, especially in wood and plant materials. Infection usually occurs through contact with a contaminated environment through skin injuries, which makes affected people vulnerable, especially among gardeners and farmers.

History of the disease and interesting historical facts

Sporotrichosis was first described in the scientific literature in 1898, when a physician named Rudolf Frisch identified the disease in one of his patients. Throughout the 20th century, sporotrichosis has been studied in various parts of the world, including the United States and Latin American countries, where the disease has the highest incidence rates. Interestingly, in the 2000s, sporotrichosis became known as the “gardener’s disease,” as most cases are observed among people working in horticulture and agronomy. Various epidemics of sporotrichosis have been reported in many countries, highlighting the need for active surveillance of the disease.

Epidemiology

According to recent data, the incidence of sporotrichosis varies by region. In some Latin American countries, such as Brazil and Mexico, the achieved rates of case notification can be up to 4 cases per 100,000 population per year. In the United States, sporotrichosis has also been reported, but the incidence is much lower, with approximately 0.5 cases per 100,000 population. In recent years, there has been an increasing trend in the number of cases, which is associated with climate change and the increase in the number of pets, especially cats, which can carry Sporothrix schenckii.

Genetic predisposition to this disease

Genetic predisposition to sporotrichosis is currently under investigation. There is evidence that certain genes involved in the immune response may influence susceptibility to the disease. For example, polymorphisms in genes involved in cytokine production may alter an individual's susceptibility to infection. To date, there are no specific mutations that have been clearly associated with the development of sporotrichosis, but further research may reveal more precise molecular mechanisms and genetic factors that contribute to the development of the disease.

Risk factors for the development of this disease

Risk factors that contribute to the development of sporotrichosis include:

• Contact with plant materials, especially those that are prickly or damaged.
• Work in gardening, agronomy or other work related to soil and plants.
• The presence of open wounds or skin lesions that may serve as entry points for infection.
• Immunodeficiency states caused by HIV, diabetes or long-term corticosteroid therapy.
• Pets, especially cats, can carry the fungus and transmit it through bites or cuts.

Diagnosis of this disease

Diagnosis of sporotrichosis is based on a combination of clinical, laboratory and radiological data. The main symptoms include:

• The appearance of nodules on the skin, which can develop into ulcers.
• Localized or generalized lymphadenitis.
• Systemic manifestations in severe forms, such as fever and weight loss.

Laboratory tests include:

• Microscopic examination of scrapings and biopsies, making it possible to visualize the fungus.
• Cultural studies to determine the pathogen.
• Serologic tests, although their specificity and sensitivity may vary.

Radiological examinations such as X-ray or CT scan may be helpful in identifying pulmonary forms of the disease. Differential diagnosis should include other fungal infections and bacterial skin diseases.

Treatment

Treatment of sporotrichosis depends on the form of the disease and its severity. General approaches to treatment may include:

• Antifungal therapy as the main treatment for all forms of the disease.
• Surgical intervention in cases of deep or extensive lesions to remove necrotic tissue.
• Systemic and local antifungals such as itraconazole or terbinafine.

Pharmacological treatment usually begins with oral antifungals such as itraconazole for 3–6 months. In severe and disseminated cases, a combination of antifungals including amphotericin B may be required. Surgical treatment is recommended in cases of deep infection or abscess formation.

List of medications used to treat this disease

• Itraconazole
• Amphotericin B
• Terbinafine
• Caspofungin

Disease monitoring

Monitoring of patients with sporotrichosis involves regular clinical examinations and laboratory testing. Key monitoring steps include:

• Evaluation of the clinical response to therapy 2-4 weeks after the start of treatment.
• Periodic monitoring of infectious markers.
• Evaluation of possible complications such as systemic involvement.

The prognosis with early diagnosis and adequate treatment is usually favorable, but in severe cases, serious complications such as generalization of the infection may develop.

Age-related features of the disease

Sporotrichosis can occur in people of different age groups, but the clinical course of the disease may vary. In children, symptoms are often less pronounced, while in elderly patients with weakened immunity, sporotrichosis can be more severe. In old age, the likelihood of the infection spreading to internal organs and systems also increases.

Questions and Answers

• What is sporotrichosis? Sporotrichosis is a fungal infection caused by fungi of the genus Sporothrix, most often affecting the skin and underlying tissues, but can also have generalized forms.
• What are the main symptoms of sporotrichosis? The main symptoms include skin nodules that may develop into ulcers, as well as lymphadenitis and systemic manifestations in severe forms.
• How is sporotrichosis diagnosed? Diagnosis is based on clinical features, laboratory tests such as microscopy and culture, and radiological examinations.
• How is sporotrichosis treated? Treatment involves systemic antifungals such as itraconazole and, in severe cases, surgery.
• What is the prognosis for treating sporotrichosis? The prognosis is favorable in most cases with timely treatment, but severe complications are possible in advanced forms of the disease.